Company intelligence / Profile preview

Prestige BioPharma Korea

Osong, Chungcheongbuk-do, South Koreapbk.org ↗

Ownership: Private
Employees: ~2500
Development stage: Other

Overview

Prestige BioPharma Korea develops biosimilars and novel monoclonal antibodies. Its lead program—HD201, a Herceptin® biosimilar—has completed Phase III trials with positive results. Other programs include Avastin® and Humira® biosimilars at advanced clinical stages. The first-in-class anti-pancreatic cancer antibody PBP1510 has received Orphan Drug status from major regulatory agencies. The firm also expanded into vaccine manufacturing during COVID‑19 as part of a consortium producing Sputnik V vaccine substance in South Korea.

Therapeutic areas: Oncology
Modalities: Monoclonal antibodyBiosimilarVaccine
Industry: Biotech

Partnerships

Huons Global consortium for Sputnik V COVID‑19 vaccine manufacturing

Beyond the preview

Go deeper on Prestige BioPharma Korea.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Prestige BioPharma Korea.

Explore the full profile